Immunocore (IMCR) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

IMCR Stock Forecast


Immunocore stock forecast is as follows: an average price target of $70.75 (represents a 120.27% upside from IMCR’s last price of $32.12) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

IMCR Price Target


The average price target for Immunocore (IMCR) is $70.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $24.00. This represents a potential 120.27% upside from IMCR's last price of $32.12.

IMCR Analyst Ratings


Buy

According to 7 Wall Street analysts, Immunocore's rating consensus is 'Buy'. The analyst rating breakdown for IMCR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Immunocore Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024David DaiUBS---25.05%-25.28%
Sep 16, 2024Justin KimOppenheimer--169.29%177.09%
Sep 12, 2024Graig SuvannavejhMizuho Securities--115.31%124.16%
Aug 28, 2024Patrick TrucchioH.C. Wainwright--180.03%211.33%
Aug 09, 2024Peter LawsonBarclays--74.05%105.48%
May 13, 2024Graig SuvannavejhMizuho Securities--53.71%173.97%
May 09, 2024Bill MaughanCanaccord Genuity--9.26%108.59%
Dec 15, 2022Rajan SharmaGoldman Sachs--34.63%149.07%
Sep 09, 2022Michael YeeJefferies--54.43%111.71%
Row per page
Go to

The latest Immunocore stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $24.00, which represents a -25.05% decrease from the stock price at the time of the forecast ($32.02), and a -25.28% decrease from IMCR last price ($32.12).

Immunocore Price Target by Period


1M3M12M
# Anlaysts147
Avg Price Target$24.00$71.25$72.29
Last Closing Price$32.12$32.12$32.12
Upside/Downside-25.28%121.82%125.06%

In the current month, the average price target of Immunocore stock is $24.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -25.28% decrease as opposed to Immunocore's last price of $32.12. This month's average price target is down -66.32% compared to last quarter, and down -66.80% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024OppenheimerUnderperformUnderperformHold
Oct 24, 2024UBSBuyBuyHold
Oct 24, 2024H.C. WainwrightBuyBuyHold
Oct 24, 2024UBSSellInitialise
Oct 07, 2024NeedhamUnderperformUnderperformHold
Oct 07, 2024OppenheimerBuyBuyHold
Oct 07, 2024GuggenheimNeutralDowngrade
Sep 16, 2024OppenheimerOutperformOutperformHold
Sep 16, 2024Cowen & Co.BuyBuyHold
Aug 28, 2024OppenheimerBuyBuyHold
Row per page
Go to

Immunocore's last stock rating was published by Oppenheimer on Oct 24, 2024. The company gave IMCR a "Underperform" rating, the same as its previous rate.

Immunocore Financial Forecast


Immunocore Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue------------$105.64M$51.49M-$44.54M$48.06M$41.20M$32.00M$22.47M$6.59M$5.92M$5.73M$8.27M$7.42M
Avg Forecast$91.86M$93.20M$92.95M$92.44M$92.14M$90.42M$88.25M$86.04M$84.53M$78.94M$74.58M$69.47M$66.58M$62.79M$57.76M$49.51M$52.20M$37.39M$20.97M$8.34M$7.79M$7.36M$7.83M$11.47M$6.46M
High Forecast$104.69M$106.22M$105.93M$105.34M$105.00M$103.04M$100.57M$91.36M$88.15M$89.96M$84.99M$79.16M$76.67M$71.56M$65.82M$56.43M$59.49M$37.39M$20.97M$8.34M$7.79M$7.36M$7.83M$11.47M$6.46M
Low Forecast$87.32M$88.59M$88.35M$87.86M$87.57M$85.94M$83.88M$83.10M$83.02M$75.03M$70.89M$66.03M$58.22M$59.68M$54.90M$47.06M$49.62M$37.39M$20.97M$8.34M$7.79M$7.36M$7.83M$11.47M$6.46M
# Analysts33334446109510115595447551075
Surprise %------------1.59%0.82%-0.90%0.92%1.10%1.53%2.69%0.85%0.81%0.73%0.72%1.15%

Immunocore's average Quarter revenue forecast for Mar 24 based on 10 analysts is $69.47M, with a low forecast of $66.03M, and a high forecast of $79.16M. IMCR's average Quarter revenue forecast represents a -34.24% decrease compared to the company's last Quarter revenue of $105.64M (Dec 23).

Immunocore EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts33334446109510115595447551075
EBITDA------------$-37.54M$14.06M-$-13.56M$-19.90M$-6.94M$-12.02M$-14.77M$-36.11M$-29.23M$-32.71M$-30.05M$-17.60M
Avg Forecast$-63.83M$-64.76M$-64.58M$-64.22M$-64.01M$-62.82M$-61.31M$-59.78M$-58.73M$-54.85M$-51.82M$-48.26M$-46.26M$-43.63M$-40.13M$-34.40M$-36.27M$-25.48M$-14.29M$-15.89M$-5.31M$-5.02M$-5.34M$-19.39M$-4.40M
High Forecast$-60.67M$-61.55M$-61.38M$-61.05M$-60.84M$-59.71M$-58.28M$-57.74M$-57.68M$-52.13M$-49.25M$-45.87M$-40.45M$-41.47M$-38.14M$-32.70M$-34.47M$-25.48M$-14.29M$-12.71M$-5.31M$-5.02M$-5.34M$-15.51M$-4.40M
Low Forecast$-72.74M$-73.80M$-73.60M$-73.19M$-72.95M$-71.59M$-69.87M$-63.47M$-61.24M$-62.50M$-59.05M$-55.00M$-53.27M$-49.72M$-45.73M$-39.20M$-41.33M$-25.48M$-14.29M$-19.06M$-5.31M$-5.02M$-5.34M$-23.26M$-4.40M
Surprise %------------0.81%-0.32%-0.39%0.55%0.27%0.84%0.93%6.80%5.83%6.13%1.55%4.00%

11 analysts predict IMCR's average Quarter EBITDA for Dec 23 to be $-46.26M, with a high of $-40.45M and a low of $-53.27M. This is -429.08% lower than Immunocore's previous annual EBITDA (Sep 23) of $14.06M.

Immunocore Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts33334446109510115595447551075
Net Income------------$-26.42M$1.90M-$-16.70M$-25.20M$6.23M$-6.12M$-16.13M$-39.39M$-30.13M$-32.96M$-29.04M$-18.88M
Avg Forecast$-8.32M$-6.66M$-5.41M$-3.75M$-15.76M$-12.32M$-10.39M$-10.62M$-10.11M$-13.54M$-19.86M$-15.48M$-10.35M$-15.26M$-16.24M$-14.86M$1.14M$-12.59M$-30.17M$-17.35M$-39.90M$-41.60M$-34.97M$-18.73M$-39.00M
High Forecast$-7.79M$-6.23M$-5.06M$-3.51M$-14.74M$-11.53M$-9.72M$-3.54M$-2.22M$-12.67M$-18.58M$-14.48M$-2.59M$-14.28M$-15.19M$-13.90M$1.35M$-12.59M$-30.17M$-13.88M$-39.90M$-41.60M$-34.97M$-14.99M$-39.00M
Low Forecast$-9.84M$-7.87M$-6.39M$-4.43M$-18.62M$-14.56M$-12.27M$-18.58M$-22.94M$-16.00M$-23.46M$-18.29M$-17.75M$-18.03M$-19.18M$-17.55M$1.07M$-12.59M$-30.17M$-20.82M$-39.90M$-41.60M$-34.97M$-22.48M$-39.00M
Surprise %------------2.55%-0.12%-1.12%-22.09%-0.49%0.20%0.93%0.99%0.72%0.94%1.55%0.48%

Immunocore's average Quarter net income forecast for Dec 23 is $-10.35M, with a range of $-17.75M to $-2.59M. IMCR's average Quarter net income forecast represents a -643.84% decrease compared to the company's last Quarter net income of $1.90M (Sep 23).

Immunocore SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts33334446109510115595447551075
SG&A------------$64.19M$10.99M-$33.30M$43.14M$25.88M$24.51M$20.11M$24.37M$20.05M$23.80M$20.18M$14.17M
Avg Forecast$143.40M$145.49M$145.09M$144.29M$143.82M$141.14M$137.75M$134.30M$131.95M$123.22M$116.42M$108.43M$103.94M$98.02M$90.16M$77.29M$81.49M$58.37M$32.73M$13.02M$12.15M$11.49M$12.23M$17.90M$10.08M
High Forecast$163.42M$165.80M$165.35M$164.44M$163.90M$160.85M$156.98M$142.60M$137.59M$140.42M$132.67M$123.57M$119.68M$111.70M$102.75M$88.08M$92.86M$58.37M$32.73M$13.02M$12.15M$11.49M$12.23M$17.90M$10.08M
Low Forecast$136.30M$138.29M$137.91M$137.15M$136.70M$134.15M$130.93M$129.72M$129.59M$117.12M$110.65M$103.06M$90.89M$93.17M$85.70M$73.46M$77.45M$58.37M$32.73M$13.02M$12.15M$11.49M$12.23M$17.90M$10.08M
Surprise %------------0.62%0.11%-0.43%0.53%0.44%0.75%1.54%2.00%1.75%1.95%1.13%1.41%

Immunocore's average Quarter SG&A projection for Mar 24 is $108.43M, based on 10 Wall Street analysts, with a range of $103.06M to $123.57M. The forecast indicates a 68.91% rise compared to IMCR last annual SG&A of $64.19M (Dec 23).

Immunocore EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts33334446109510115595447551075
EPS------------$-0.00$0.04-$-0.35$-0.54$0.13$-0.14$-0.37$-0.90$-0.69$-0.75$-0.76$-0.49
Avg Forecast$-0.16$-0.13$-0.10$-0.07$-0.30$-0.23$-0.20$-0.20$-0.19$-0.26$-0.38$-0.29$-0.20$-0.29$-0.31$-0.28$0.02$-0.25$-0.60$-0.84$-0.80$-0.83$-0.70$-0.60$-0.78
High Forecast$-0.15$-0.12$-0.10$-0.07$-0.28$-0.22$-0.18$-0.07$-0.04$-0.24$-0.35$-0.27$-0.05$-0.27$-0.29$-0.26$0.03$-0.25$-0.60$-0.84$-0.80$-0.83$-0.70$-0.60$-0.78
Low Forecast$-0.19$-0.15$-0.12$-0.08$-0.35$-0.28$-0.23$-0.35$-0.43$-0.30$-0.44$-0.35$-0.34$-0.34$-0.36$-0.33$0.02$-0.25$-0.60$-0.84$-0.80$-0.83$-0.70$-0.60$-0.78
Surprise %------------0.00%-0.14%-1.24%-24.99%-0.52%0.23%0.44%1.13%0.83%1.07%1.27%0.63%

According to 11 Wall Street analysts, Immunocore's projected average Quarter EPS for Dec 23 is $-0.20, with a low estimate of $-0.34 and a high estimate of $-0.05. This represents a -590.20% decrease compared to IMCR previous annual EPS of $0.04 (Sep 23).

Immunocore Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences--1857.23%Buy
LRMRLarimar Therapeutics--231.65%Buy
LYRALyra Therapeutics--177.78%Hold
ERASErasca--150.00%Buy
KALVKalVista Pharmaceuticals--142.98%Buy
IMCRImmunocore--120.27%Buy
VRDNViridian Therapeutics--93.27%Buy
DSGNDesign Therapeutics--73.61%Buy
PCVXVaxcyte--40.29%Buy
MIRMMirum Pharmaceuticals--31.67%Buy
DICEDICE Therapeutics--26.18%Buy
NUVLNuvalent--20.32%Buy
ACLXArcellx---4.84%Buy
GRCLGracell Bio---41.46%Buy

IMCR Forecast FAQ


Is Immunocore a good buy?

Yes, according to 7 Wall Street analysts, Immunocore (IMCR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of IMCR's total ratings.

What is IMCR's price target?

Immunocore (IMCR) average price target is $70.75 with a range of $24 to $100, implying a 120.27% from its last price of $32.12. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Immunocore stock go up soon?

According to Wall Street analysts' prediction for IMCR stock, the company can go up by 120.27% (from the last price of $32.12 to the average price target of $70.75), up by 211.33% based on the highest stock price target, and down by -25.28% based on the lowest stock price target.

Can Immunocore stock reach $50?

IMCR's average twelve months analyst stock price target of $70.75 supports the claim that Immunocore can reach $50 in the near future.

What is Immunocore's current price target trend?

1 Wall Street analyst forecast a $24 price target for Immunocore (IMCR) this month, down -25.28% from its last price of $32.12. Compared to the last 3 and 12 months, the average price target increased by 121.82% and increased by 125.06%, respectively.

What are Immunocore's analysts' financial forecasts?

Immunocore's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $356.84M (high $399.96M, low $340.5M), average EBITDA is $-248M (high $-237M, low $-278M), average net income is $-49.08M (high $-39.527M, low $-64.023M), average SG&A $557.01M (high $624.33M, low $531.5M), and average EPS is $-0.929 (high $-0.748, low $-1.212). IMCR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $370.46M (high $422.17M, low $352.12M), average EBITDA is $-257M (high $-245M, low $-293M), average net income is $-24.142M (high $-22.588M, low $-28.524M), average SG&A $578.27M (high $659M, low $549.64M), and average EPS is $-0.457 (high $-0.428, low $-0.54).

Did the IMCR's actual financial results beat the analysts' financial forecasts?

Based on Immunocore's last annual report (Dec 2023), the company's revenue was $249.43M, beating the average analysts forecast of $236.65M by 5.40%. Apple's EBITDA was $-59.649M, missing the average prediction of $-164M by -63.72%. The company's net income was $-55.287M, missing the average estimation of $-56.709M by -2.51%. Apple's SG&A was $144.5M, missing the average forecast of $369.4M by -60.88%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-1.074 by -99.90%. In terms of the last quarterly report (Dec 2023), Immunocore's revenue was $105.64M, beating the average analysts' forecast of $66.58M by 58.65%. The company's EBITDA was $-37.543M, missing the average prediction of $-46.262M by -18.85%. Immunocore's net income was $-26.417M, beating the average estimation of $-10.355M by 155.12%. The company's SG&A was $64.2M, missing the average forecast of $103.94M by -38.24%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.196 by -99.75%